Inhibikase Therapeutics, Inc. (IKT) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 79.57K | 116.41K |
| Revenue Growth % | - | - | - | - | - | -100% | -100% | -100% | -100% | -100% | 991.33% | 1676.71% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 159.2K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 656800% | 8.25% | 136.76% |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | -6.57K | -6.57K | -6.57K | -6.57K | -6.57K | 73K | -42.79K |
| Gross Margin % | - | - | - | - | - | - | - | - | - | -656700% | 91.75% | -36.76% |
| Gross Profit Growth % | - | 100% | 100% | 100% | 100% | 0% | -109% | 84.65% | -111.04% | -111.22% | 1201.27% | 98.56% |
| Operating Expenses | 18.22M | 13.78M | 12.77M | 10.83M | 14.6M | 12.92M | 5.83M | 5.05M | 4.78M | 4.4M | 4.84M | 6.16M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | 99999900% | 6085.13% | 5291.3% |
| Selling, General & Admin | 7.38M | 6.77M | 5.61M | 5.92M | 5.25M | 5.74M | 1.64M | 1.97M | 2.02M | 1.39M | 1.62M | 1.62M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | 99999900% | 2031.35% | 1394.99% |
| Research & Development | 10.84M | 6.36M | 7.65M | 5.27M | 10.51M | 7.19M | 4.19M | 3.08M | 2.75M | 3M | 3.23M | 4.54M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | 99999900% | 4053.78% | 3896.31% |
| Other Operating Expenses | 0 | 642.17K | -492.83K | -358.42K | -1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.22M | -13.78M | -12.77M | -10.83M | -14.6M | -12.93M | -5.83M | -5.05M | -4.78M | -4.4M | -4.77M | -6.2M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5993.38% | -5328.07% |
| Operating Income Growth % | -24.78% | -6.55% | -119.11% | -114.48% | -205.25% | -193.6% | -22.2% | 18.57% | -1.43% | -1.58% | -5.67% | -33.67% |
| EBITDA | -18.22M | -13.13M | -12.74M | -10.81M | -14.59M | -12.92M | -5.82M | -5.04M | -4.78M | -4.4M | -4.76M | -6.04M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5985.13% | -5191.3% |
| EBITDA Growth % | -24.89% | -1.64% | -118.95% | -114.28% | -205.4% | -193.89% | -22.23% | 16.53% | -1.4% | -1.55% | -5.56% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 23.69K | 24.16K | 12.65K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 6.57K | 159.2K |
| EBIT | -18.22M | -13.13M | -13.26M | -11.19M | -15.76M | -12.13M | -5.83M | -5.05M | -4.78M | -4.18M | -4.6M | -5.78M |
| Net Interest Income | 1.46M | 1.04M | 838.09K | 916.75K | 919.27K | 796.12K | 49.41K | 90.93K | 132.72K | 225.63K | 173.68K | 424.44K |
| Interest Income | 1.46M | 1.04M | 838.09K | 916.75K | 919.27K | 796.12K | 49.41K | 90.93K | 132.72K | 225.63K | 173.68K | 424.44K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.83M | 1.04M | 838.09K | 916.75K | 919.27K | 796.12K | 49.41K | 90.93K | 132.72K | 225.63K | 173.68K | 424.44K |
| Pretax Income | -16.38M | -12.73M | -11.93M | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5775.11% | -4963.46% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -16.38M | -12.73M | -11.93M | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M |
| Net Margin % | - | - | - | - | - | - | - | - | - | -99999900% | -5775.11% | -4963.46% |
| Net Income Growth % | -19.75% | -4.96% | -106.48% | -99.93% | -194.19% | -190.4% | -25.74% | 14.16% | -3.84% | 2.36% | -2.24% | -24.53% |
| Net Income (Continuing) | -16.38M | -12.73M | -11.93M | -9.92M | -13.68M | -12.13M | -5.78M | -4.96M | -4.65M | -4.18M | -4.6M | -5.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17 | -0.13 | -0.13 | -0.11 | -0.15 | -0.17 | -0.65 | -0.66 | -0.73 | -0.68 | -0.86 | -1.11 |
| EPS Growth % | -13.33% | 23.53% | 80% | 83.33% | 79.45% | 75% | 24.42% | 40.54% | 25.51% | 33.33% | 19.63% | -0.91% |
| EPS (Basic) | -0.17 | -0.13 | -0.13 | -0.11 | -0.15 | -0.17 | -0.65 | -0.66 | -0.73 | -0.68 | -0.86 | -1.11 |
| Diluted Shares Outstanding | 98.31M | 98.31M | 90.05M | 90.01M | 89.54M | 69.36M | 8.88M | 7.54M | 6.34M | 6.19M | 5.34M | 5.23M |
| Basic Shares Outstanding | 98.31M | 98.31M | 90.05M | 90.01M | 89.54M | 69.36M | 8.88M | 7.54M | 6.34M | 6.19M | 5.34M | 5.23M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |